Mineral and bone disorder in Chinese dialysis patients: a multicenter study
<p>Abstract</p> <p>Background</p> <p>Mineral and bone disorder (MBD) in patients with chronic kidney disease is associated with increased morbidity and mortality. Studies regarding the status of MBD treatment in developing countries, especially in Chinese dialysis patie...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-09-01
|
Series: | BMC Nephrology |
Subjects: | |
Online Access: | http://www.biomedcentral.com/1471-2369/13/116 |
id |
doaj-e480c83a3cff46809e46375917de6970 |
---|---|
record_format |
Article |
spelling |
doaj-e480c83a3cff46809e46375917de69702020-11-24T21:11:28ZengBMCBMC Nephrology1471-23692012-09-0113111610.1186/1471-2369-13-116Mineral and bone disorder in Chinese dialysis patients: a multicenter studyKong XiangleiZhang LuxiaZhang LingChen NanGu YongYu XueqingLiu WenhuChen JianghuaPeng LirenYuan WeijieWu HuaChen WeiFan MinhuaHe LiqunDing FengChen XiangmeiXiong ZuyingZhang JinyuanJia QiangShi WeiXing ChangyingTang XiaolingHou FanfanShu GuiyangMei ChanglinWang LiXu DongmeiNi ZhaohuiZuo LiWang MeiWang Haiyan<p>Abstract</p> <p>Background</p> <p>Mineral and bone disorder (MBD) in patients with chronic kidney disease is associated with increased morbidity and mortality. Studies regarding the status of MBD treatment in developing countries, especially in Chinese dialysis patients are extremely limited.</p> <p>Methods</p> <p>A cross-sectional study of 1711 haemodialysis (HD) patients and 363 peritoneal dialysis (PD) patients were enrolled. Parameters related to MBD, including serum phosphorus (P), calcium (Ca), intact parathyroid hormone (iPTH) were analyzed. The achievement of MBD targets was compared with the results from the Dialysis Outcomes and Practice Study (DOPPS) 3 and DOPPS 4. Factors associated with hyperphosphatemia were examined.</p> <p>Results</p> <p>Total 2074 dialysis patients from 28 hospitals were involved in this study. Only 38.5%, 39.6% and 26.6% of them met the Kidney Disease Outcomes Quality Initiative (K/DOQI) defined targets for serum P, Ca and iPTH levels. Serum P and Ca levels were statistically higher (P < 0.05) in the HD patients compared with those of PD patients, which was (6.3 ± 2.1) mg/dL vs (5.7 ± 2.0) mg/dL and (9.3 ± 1.1) mg/dL vs (9.2 ± 1.1) mg/dL, respectively. Serum iPTH level were statistically higher in the PD patients compared with those of HD patients (P = 0.03). The percentage of patients reached the K/DOQI targets for P (37.6% vs 49.8% vs 54.5%, P < 0.01), Ca (38.6% vs 50.4% vs 56.0%, P < 0.01) and iPTH (26.5% vs 31.4% vs 32.1%, P < 0.01) were lower among HD patients, compared with the data from DOPPS 3 and DOPPS 4. The percentage of patients with serum phosphorus level above 5.5 mg/dL was 57.4% in HD patients and 47.4% in PD patients. Age, dialysis patterns and region of residency were independently associated with hyperphosphatemia.</p> <p>Conclusions</p> <p>Status of MBD is sub-optimal among Chinese patients receiving dialysis. The issue of hyperphosphatemia is prominent and needs further attention.</p> http://www.biomedcentral.com/1471-2369/13/116End stage renal diseaseMineral and bone disorderEpidemiology |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kong Xianglei Zhang Luxia Zhang Ling Chen Nan Gu Yong Yu Xueqing Liu Wenhu Chen Jianghua Peng Liren Yuan Weijie Wu Hua Chen Wei Fan Minhua He Liqun Ding Feng Chen Xiangmei Xiong Zuying Zhang Jinyuan Jia Qiang Shi Wei Xing Changying Tang Xiaoling Hou Fanfan Shu Guiyang Mei Changlin Wang Li Xu Dongmei Ni Zhaohui Zuo Li Wang Mei Wang Haiyan |
spellingShingle |
Kong Xianglei Zhang Luxia Zhang Ling Chen Nan Gu Yong Yu Xueqing Liu Wenhu Chen Jianghua Peng Liren Yuan Weijie Wu Hua Chen Wei Fan Minhua He Liqun Ding Feng Chen Xiangmei Xiong Zuying Zhang Jinyuan Jia Qiang Shi Wei Xing Changying Tang Xiaoling Hou Fanfan Shu Guiyang Mei Changlin Wang Li Xu Dongmei Ni Zhaohui Zuo Li Wang Mei Wang Haiyan Mineral and bone disorder in Chinese dialysis patients: a multicenter study BMC Nephrology End stage renal disease Mineral and bone disorder Epidemiology |
author_facet |
Kong Xianglei Zhang Luxia Zhang Ling Chen Nan Gu Yong Yu Xueqing Liu Wenhu Chen Jianghua Peng Liren Yuan Weijie Wu Hua Chen Wei Fan Minhua He Liqun Ding Feng Chen Xiangmei Xiong Zuying Zhang Jinyuan Jia Qiang Shi Wei Xing Changying Tang Xiaoling Hou Fanfan Shu Guiyang Mei Changlin Wang Li Xu Dongmei Ni Zhaohui Zuo Li Wang Mei Wang Haiyan |
author_sort |
Kong Xianglei |
title |
Mineral and bone disorder in Chinese dialysis patients: a multicenter study |
title_short |
Mineral and bone disorder in Chinese dialysis patients: a multicenter study |
title_full |
Mineral and bone disorder in Chinese dialysis patients: a multicenter study |
title_fullStr |
Mineral and bone disorder in Chinese dialysis patients: a multicenter study |
title_full_unstemmed |
Mineral and bone disorder in Chinese dialysis patients: a multicenter study |
title_sort |
mineral and bone disorder in chinese dialysis patients: a multicenter study |
publisher |
BMC |
series |
BMC Nephrology |
issn |
1471-2369 |
publishDate |
2012-09-01 |
description |
<p>Abstract</p> <p>Background</p> <p>Mineral and bone disorder (MBD) in patients with chronic kidney disease is associated with increased morbidity and mortality. Studies regarding the status of MBD treatment in developing countries, especially in Chinese dialysis patients are extremely limited.</p> <p>Methods</p> <p>A cross-sectional study of 1711 haemodialysis (HD) patients and 363 peritoneal dialysis (PD) patients were enrolled. Parameters related to MBD, including serum phosphorus (P), calcium (Ca), intact parathyroid hormone (iPTH) were analyzed. The achievement of MBD targets was compared with the results from the Dialysis Outcomes and Practice Study (DOPPS) 3 and DOPPS 4. Factors associated with hyperphosphatemia were examined.</p> <p>Results</p> <p>Total 2074 dialysis patients from 28 hospitals were involved in this study. Only 38.5%, 39.6% and 26.6% of them met the Kidney Disease Outcomes Quality Initiative (K/DOQI) defined targets for serum P, Ca and iPTH levels. Serum P and Ca levels were statistically higher (P < 0.05) in the HD patients compared with those of PD patients, which was (6.3 ± 2.1) mg/dL vs (5.7 ± 2.0) mg/dL and (9.3 ± 1.1) mg/dL vs (9.2 ± 1.1) mg/dL, respectively. Serum iPTH level were statistically higher in the PD patients compared with those of HD patients (P = 0.03). The percentage of patients reached the K/DOQI targets for P (37.6% vs 49.8% vs 54.5%, P < 0.01), Ca (38.6% vs 50.4% vs 56.0%, P < 0.01) and iPTH (26.5% vs 31.4% vs 32.1%, P < 0.01) were lower among HD patients, compared with the data from DOPPS 3 and DOPPS 4. The percentage of patients with serum phosphorus level above 5.5 mg/dL was 57.4% in HD patients and 47.4% in PD patients. Age, dialysis patterns and region of residency were independently associated with hyperphosphatemia.</p> <p>Conclusions</p> <p>Status of MBD is sub-optimal among Chinese patients receiving dialysis. The issue of hyperphosphatemia is prominent and needs further attention.</p> |
topic |
End stage renal disease Mineral and bone disorder Epidemiology |
url |
http://www.biomedcentral.com/1471-2369/13/116 |
work_keys_str_mv |
AT kongxianglei mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT zhangluxia mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT zhangling mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT chennan mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT guyong mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT yuxueqing mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT liuwenhu mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT chenjianghua mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT pengliren mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT yuanweijie mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT wuhua mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT chenwei mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT fanminhua mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT heliqun mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT dingfeng mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT chenxiangmei mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT xiongzuying mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT zhangjinyuan mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT jiaqiang mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT shiwei mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT xingchangying mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT tangxiaoling mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT houfanfan mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT shuguiyang mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT meichanglin mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT wangli mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT xudongmei mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT nizhaohui mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT zuoli mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT wangmei mineralandbonedisorderinchinesedialysispatientsamulticenterstudy AT wanghaiyan mineralandbonedisorderinchinesedialysispatientsamulticenterstudy |
_version_ |
1716753300082130944 |